UiPath - PATH Stock Forecast, Price & News

UiPath Inc. provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, and Japan. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization. Its platform combines artificial intelligence with desktop recording, back-end mining of both human activity and system logs, and intuitive visualization tools, which enables users to discover, analyze, and identify processes to automate in a centralized portal; offers low-code development environments that allows users in an organization to create attended and unattended automations without any prior knowledge of coding; deploys robots in highly immersive attended experiences or in standalone, unattended modes behind the scenes, and can leverage native connectors built for commonly used line-of-business applications; offers centralized tools designed to manage, test, and deploy automations and ML models across the enterprise; allows customers to manage long running processes that orchestrate work between robots and humans; and enable users to track, measure, and forecast the performance of automation in their enterprise and help businesses ensure compliance with business standards. In addition, the company provides maintenance and support for its software, as well as professional services, such as training and implementation services to facilitate the adoption of its platform. It serves banking, healthcare, financial services, and government entities. UiPath Inc. was founded in 2005 and is headquartered in New York, New York.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the company. Royal Bank of Canada cut their price target on UiPath from $32.00 to $27.00 in a research note on Tuesday, May 31st. Canaccord Genuity Group reissued a "buy" rating and issued a $25.00 price target on shares of UiPath in a report on Thursday, July 7th. Credit Suisse Group lowered their price target on UiPath from $57.50 to $45.00 in a report on Thursday, June 2nd. Barclays lowered their price target on UiPath from $36.00 to $25.00 in a report on Friday, May 20th. Finally, KeyCorp lowered their price target on UiPath from $34.00 to $23.00 and set an "overweight" rating on the stock in a report on Monday, April 25th. Four analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to data from MarketBeat, UiPath presently has an average rating of "Moderate Buy" and a consensus target price of $36.06.

UiPath Trading Down 0.2 %

PATH traded down $0.05 during trading on Friday, hitting $21.24. The company's stock had a trading volume of 4,132,447 shares, compared to its average volume of 3,981,793. UiPath has a twelve month low of $13.66 and a twelve month high of $66.07. The business's fifty day simple moving average is $19.34 and its 200 day simple moving average is $23.84. The firm has a market capitalization of $11.57 billion, a price-to-earnings ratio of -27.58 and a beta of 0.09.

UiPath (NASDAQ:PATH - Get Rating) last released its earnings results on Wednesday, June 1st. The healthcare company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.07). The firm had revenue of $245.07 million during the quarter, compared to analysts' expectations of $225.37 million. UiPath had a negative net margin of 42.95% and a negative return on equity of 18.47%. The business's revenue was up 31.6% compared to the same quarter last year. During the same quarter last year, the business earned ($0.81) EPS. As a group, equities research analysts forecast that UiPath will post -0.59 earnings per share for the current fiscal year.

Insider Buying and Selling at UiPath

In other news, Director Kimberly Hammonds sold 2,521 shares of UiPath stock in a transaction on Tuesday, June 21st. The stock was sold at an average price of $18.70, for a total value of $47,142.70. Following the completion of the sale, the director now directly owns 100,662 shares of the company's stock, valued at $1,882,379.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 31.88% of the company's stock.